Artiva Biotherapeutics, Inc.
NASDAQ:ARTVBiotechnology
-$0.34 today
- Market cap
- $186.36M
- Beta
- 2.40
- P/E (TTM)
- -2.7
- EPS (TTM)
- -$3.53
Volume 0.97M
Average 0.48M
ARTV Net Debt
Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.
Artiva Biotherapeutics, Inc.NASDAQ: ARTV
Net Debt · Q1 FY2026 · quarter ended Mar 2026
Net debt remains negative
Q1 FY2026 net debt was -$10.69M, compared with -$16.41M a year earlier.
Context
- Net debt amounted to 10.1% of total assets at the end of Q1 FY2026, up 1.5 pp from a year earlier.
- Net debt grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether net debt keeps rising in the next quarterly balance sheet after a +34.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Debt history
USD · from the balance sheet
- Latest · FY2025
- (15.76M) USD
- Year-over-year change
- +39.1%
| Period | Period end | Net Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (15.76M) | +39.1% |
| FY2024 | 2024-12-31 | (25.88M) | +29.3% |
| FY2023 | 2023-12-31 | (36.59M) | +56.0% |
| FY2022 | 2022-12-31 | (83.08M) | +47.8% |
| FY2021 | 2021-12-31 | (159.18M) | — |
Net Debt vs competitors
How ARTV compares with its peers on the latest reported figures
- Peers report in different currencies, so net debt is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +34.8% is the 4th highest of 9, against a peer median of -10.1%.
- Net debt amounts to 10.1% of total assets for ARTV, versus a peer median of 26.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $6.72M USD | +2809.5% | -5.6% | 2.7% | |
| Mar 2026 | -$2.35M USD | -112.2% | — | 2.4% | |
ARTVArtiva Biotherapeutics, Inc. | Mar 2026 | -$10.69M USD | +34.8% | — | 10.1% |
| Mar 2026 | -€14.19M EUR | +69.5% | — | 29.0% | |
| Mar 2026 | -$27.07M USD | -154.3% | — | 15.2% | |
| Dec 2025 | -$37.66M USD | +51.8% | — | 67.2% | |
| Mar 2026 | -$60.05M USD | +29.2% | — | 24.8% | |
| Mar 2026 | -$70.9M USD | -49.4% | — | 49.3% | |
| Mar 2026 | -$87.53M USD | -51.7% | — | 85.7% | |
| Peer median (excluding ARTV) | — | -10.1% | -5.6% | 26.9% | |
Competitors are the stored peer set for ARTV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 160.92M | 102.53M | 53.5M | 40.24M | 26.7M |
| Short-term Investments | 0 | 0 | 23.47M | 145.19M | 81.31M |
| Net Receivables | 468K | 525K | 1.76M | 146K | 767K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 1.62M | 1.09M | 3.06M | 3.89M |
| Total Current Assets | 162.29M | 104.68M | 79.82M | 188.63M | 112.67M |
| Property, Plant & Equipment (Net) | 4.08M | 27.62M | 24.64M | 20.43M | 17.36M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 245K | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 3.56M | 517K | 650K | 525K | 919K |
| Total Non-current Assets | 7.64M | 28.38M | 25.29M | 20.95M | 18.27M |
| Total Assets | 169.93M | 133.05M | 105.11M | 209.58M | 130.94M |
| Account Payables | 1.44M | 1.1M | 614K | 1.12M | 355K |
| Short-term Debt | 0 | 0 | 0 | 0 | 3.06M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 7.3M | 10.89M | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 0 | 2.1M |
| Total Current Liabilities | 19.31M | 25.63M | 12.23M | 12.25M | 13.09M |
| Long-term Debt | 0 | 0 | 0 | 0 | 7.88M |
| Deferred Tax Liabilities | 216.41M | 216.41M | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 21.68M | 15.64M | 0 | 0 | 0 |
| Other Non-current Liabilities | 81K | 115K | 241.59M | 73K | 0 |
| Total Non-current Liabilities | 239.48M | 248.13M | 254.9M | 10.69M | 7.88M |
| Total Liabilities | 258.78M | 273.75M | 267.13M | 22.94M | 20.97M |
| Common Stock | 0 | 0 | 0 | 3K | 3K |
| Retained Earnings | (93.8M) | (152.59M) | (181.31M) | (246.68M) | (330.55M) |
| Accumulated OCI | 0 | 0 | 308K | (129K) | 103K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | (88.86M) | (140.7M) | (162.02M) | 186.64M | 109.97M |
| Total Debt | 1.74M | 19.45M | 16.91M | 14.35M | 10.94M |
| Net Debt | (159.18M) | (83.08M) | (36.59M) | (25.88M) | (15.76M) |
Artiva Biotherapeutics, Inc.
NASDAQ:ARTV
Intrinsic Alpha fair value
Locked
Current Price
$3.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.